Everolimus and bevacizumab for advanced papillary kidney cancer
In this phase 2 clinical trial, a combination of everolimus [...]
Atexolizumab plus bevacizumab for sarcomatoid kidney cancer
A study published in European Urology in July looks at [...]
ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC
Results from a phase II study of bevacizumab and erlotinib [...]
Patient-reported outcomes with atezolizumab plus bevacizumab in metastatic kidney cancer
This study describes patient-reported outcomes from the phase 3 IMmotion151 [...]
Atezolizumab and bevacizumab for non-clear cell renal cell carcinoma
In this video interview from Practice Update, Dr Brad McGregor [...]
Promising activity of pembrolizumab plus bevacizumab for metastatic kidney cancer
Results from a phase Ib/II study published in Journal of [...]
Atezolizumab and bevacizumab in patients with advanced non-clear cell renal cell carcinoma
Dr Rana McKay from University of California in San Diego, [...]
Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer
Results from this phase III trial of atezolizumab plus bevacizumab [...]
Bevacizumab plus erlotinib combination for advanced HLRCC
A recent study, published in Cancer Research and Treatment in [...]
ASCO GU 2019: Atezolizumab and bevacizumab in non-clear cell kidney cancer and sarcomatoid kidney cancer
Results from this trial for patients with non-clear cell renal [...]
